Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.

Education

Manufacturing

Pharmaceutical

Therapeutics

Vigil Neuro

Ivana Magovčević-Liebisch

Alysia Martins

Michael Cohen

Leah Gibson

Clarissa Martinez-Rubio

Donald McLaren

Jordan Jara

Julia Keefe

Shannon Ryan

Heidi Mizenko

Meghan Pagliarini

Anadina Garcia

David Gray

Cynthia Cassandro

Evangelia Hatzis

Kevin Durfee

Andreas Meier

Evan Thackaberry

Jennifer Ziolkowski

Jessica Stromme

Jonathan Houze

James King

Elizabeth Thompson

Samantha Zappia

Berkley Lynch

Dwayne Stanley

Liyue Huang

Christopher Verni

Jane Lydon

Borislav Dejanovic

Sharon Morani

Craig Bodycombe

Christian Mirescu

Kelly Neelon

Yael Mandelblat-Cerf

Weeteck Yeo

The leaders of Vigil Neuro all have experience in varying aspects of the medical and scientific industry. The team includes those with experience in research, regulatory affairs, and solution providing. All of the members have received education from notable institutions and have worked for other well-known companies prior to joining Vigil Neuro. This team is equipped with the knowledge and experience necessary to lead the company to success.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at Vigil Neuro

Board of Directors

CEO and Executive Team